Free Trial

Opthea (NASDAQ:OPT) Shares Gap Up - Here's Why

Opthea logo with Medical background
Remove Ads

Opthea Limited (NASDAQ:OPT - Get Free Report)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $3.55, but opened at $4.18. Opthea shares last traded at $3.88, with a volume of 21,497 shares.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of Opthea in a research note on Friday, February 28th. Canaccord Genuity Group upgraded shares of Opthea to a "strong-buy" rating in a research note on Tuesday, December 17th.

Get Our Latest Stock Analysis on OPT

Opthea Trading Down 0.3 %

The firm's fifty day moving average price is $4.53 and its two-hundred day moving average price is $4.04.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Hsbc Holdings PLC purchased a new position in shares of Opthea during the fourth quarter valued at approximately $556,000. Jane Street Group LLC purchased a new stake in Opthea during the third quarter valued at approximately $114,000. Citadel Advisors LLC purchased a new stake in Opthea during the fourth quarter valued at approximately $79,000. Twin Lakes Capital Management LLC purchased a new stake in Opthea during the third quarter valued at approximately $81,000. Finally, OLD Mission Capital LLC purchased a new stake in shares of Opthea in the fourth quarter worth $42,000. 55.95% of the stock is owned by hedge funds and other institutional investors.

About Opthea

(Get Free Report)

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

Read More

Should You Invest $1,000 in Opthea Right Now?

Before you consider Opthea, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.

While Opthea currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads